GlobeNewsWire
18 Jul 2026, 19:15 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b clinical trial for its 4D-150 gene therapy in wet AMD patients. — Positive long-term clinical data for a lead asset in a high-prevalence market significantly increases the probability of regulatory success and future revenue.
+0.80The 4D-150 candidate is designed to replace frequent bolus injections with a single intravitreal injection providing multi-year delivery of anti-VEGF biologics. — A substantial reduction in treatment burden creates a strong competitive advantage and higher market penetration potential compared to current standards of care.
+0.604D-150 has progressed into Phase 3 development for its lead indication of wet age-related macular degeneration. — Entry into Phase 3 indicates the company is moving toward the final stage of clinical validation, reducing the time-to-market horizon.
+0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company announced positive 2-year data from its Phase 2b clinical trial for 4D-150 in treating wet AMD.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
13h ago
